Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Residual neuromuscular blockade with continuous rocuronium infusion and dexmedetomidine pre-injection in elderly surgical patients
ChiCTR-CIC-16008519Phase 3Not yet recruiting
- Sponsor
- Renji Hospital South Campus
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rocuronium and dexmedetomidine (2 cohorts), sponsored by Renji Hospital South Campus. Primary endpoint: Residual muscle relaxation. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
rocuroniumdexmedetomidine
Beyond the preview
Go deeper on ChiCTR-CIC-16008519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-CIC-16008519.